Teleflex (NYSE:TFX) Raised to “Outperform” at Raymond James Financial

Teleflex (NYSE:TFX) was upgraded by analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a research report issued on Friday. The firm presently has a $128.00 price target on the medical technology company’s stock. Raymond James Financial’s target price would suggest a potential upside of 15.86% from the stock’s current price.

Several other research analysts also recently weighed in on TFX. Royal Bank Of Canada increased their price target on shares of Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a research report on Friday, February 27th. Needham & Company LLC upped their price objective on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company raised their target price on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Zacks Research downgraded Teleflex from a “hold” rating to a “strong sell” rating in a research report on Monday, March 2nd. Finally, Wall Street Zen lowered Teleflex from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Teleflex has a consensus rating of “Hold” and an average target price of $139.00.

Teleflex Price Performance

NYSE TFX opened at $110.48 on Friday. Teleflex has a 52 week low of $100.18 and a 52 week high of $141.91. The firm has a market capitalization of $4.88 billion, a P/E ratio of -5.38, a PEG ratio of 0.67 and a beta of 0.87. The company has a quick ratio of 2.01, a current ratio of 2.54 and a debt-to-equity ratio of 0.81. The company has a 50-day moving average price of $108.80 and a 200-day moving average price of $116.86.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). The business had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The business’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same period in the previous year, the business posted $3.89 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities research analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TFX. MassMutual Private Wealth & Trust FSB increased its stake in Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after buying an additional 77 shares in the last quarter. Banque Cantonale Vaudoise lifted its position in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after acquiring an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Teleflex in the third quarter worth about $35,000. Finally, V Square Quantitative Management LLC bought a new position in shares of Teleflex in the fourth quarter worth about $37,000. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.